Cefuroxime sodium USP/BP 98%min supplier Pharmaceutical API Antibiotic

Cefuroxime sodium is an enteral or oral second-generation cephalosporin antibiotic.
Cefuroxime sodium is an organic molecular entity.|Cefuroxime Sodium is the sodium salt form of cefuroxime and a semi-synthetic, broad-spectrum, beta-lactamase resistant, second-generation cephalosporin antibiotic with bactericidal activity. Cefuroxime sodium inhibits bacterial cell wall synthesis by inactivating penicillin binding proteins (PBPs) thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of the cell wall. Lack of cross-linking results in a reduction of cell wall stability and leads to cell lysis.|Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, GONORRHEA, and HAEMOPHILUS.
Cefuroxime sodium is marketed by Eli Lilly and Company under the trade name of Kefurox® and by Glaxo Limited under the trade name of Zinacef®. Cefuroxime sodium is an off-white to white amorphous powder. Cefuroxime sodium is an injectable second generation, semisynthetic, broad spectrum cephalosporin antibiotic with excellent activity in vitro, enhanced stability to many enterobacterial β-lactamases and favorable pharmacokinetic properties.It is used to treat a wide variety of bacterial infections. It is effective for treating meningitis, lower respiratory tract infections, urinary tract infections, gonorrhea, septicemia, skin and skin infections, bone and joint infections, and is approved for surgical prophylaxis.
White Crystalline Solid
ChEBI: Cefuroxime sodium is an organic molecular entity.